CardioVia’s Epicardial Access Feasibility Study Published in JACC: Clinical Electrophysiology

April 2022

CardioVia’s Peer-Reviewed Epicardial Access Feasibility Study Published in JACC: Clinical Electrophysiology

The results of ViaOne’s First-in-Human feasibility study were published in JACC: Clinical Electrophysiology, a leading peer-reviewed medical journal. The article reported successful pericardial access in 10 of 11 patients undergoing electrophysiology treatments, with 91% success rate. Publication in such a high-impact journal provided strong clinical validation and important international visibility for CardioVia’s innovation.

The epicardial access feasibility study represents the first clinical evaluation of the ViaOne™ Epicardial Access System in human patients. Conducted by leading electrophysiologists, the study demonstrated that the device enables safe, controlled, and reproducible pericardial access, minimizing the risks associated with traditional sharp-needle techniques.

The epicardial access feasibility study results confirm the effectiveness of ViaOne’s blunt-tip concealed needle and bio-impedance navigation design, establishing a foundation for its continued clinical use in cardiac arrhythmia management.

Publication in JACC: Clinical Electrophysiology, one of the field’s most respected journals, underscores the importance of these findings and provides global visibility for CardioVia’s work in advancing epicardial access safety and innovation.

Read more here.